Reserve your spot at London's most focused IO and biomarker summit. Two days, two streams, 400+ senior peers in March 2027.
All passes include full two-day access to all sessions, networking events, and the delegate kit. Choose the category that applies to your organisation. Early bird pricing is available until 31 July 2026.
Group bookings and speaker passes available on request. Not sure which pass applies to you? Send us an enquiry →
The only conference series dedicated to the intersection of Immuno-Oncology and Biomarker science. Built as a business development platform, not a passive knowledge event.
Two fully independent parallel tracks — Immuno-Oncology and Biomarkers and CDx — for in-depth, targeted learning directly relevant to your work.
70% of attendees are VP-level or above from top pharma, biopharma, and therapeutics companies. Every conversation is with someone who has decision-making authority.
Pre-scheduled 1:1 meetings, panel discussions, and a Drinks and Cocktail Reception on Day 1 — designed for meaningful strategic connections, not chance encounters.
London is one of the world's foremost centres for oncology drug development and biotech innovation, hosting AstraZeneca, GSK, Roche, and the UK's leading academic institutions.
The programme bridges bench science with regulatory, clinical, and commercialisation strategy — making it genuinely relevant to scientists, clinicians, and BD professionals alike.
Leaders from AstraZeneca, Roche, Merck, Johnson and Johnson, Novartis, GSK, Oxford, and more — setting the scientific and commercial standard for the field.
Fill in the form below and our team will confirm your registration and send joining instructions within 24 hours.
Or email us directly: anandhu@convolign.com · +1-617-604-3359
400+ senior leaders. Two streams. One agenda: advancing precision oncology.
Register for Boston Edition